Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$877.72 USD

877.72
351,969

-14.54 (-1.63%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $877.31 -0.41 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

by Zacks Equity Research

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

Zacks Equity Research

SANA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.

Zacks Equity Research

Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.

Zacks Equity Research

Agilent to Report Q1 Earnings: What's in the Cards for the Stock?

by Zacks Equity Research

A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.

Zacks Equity Research

SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates

by Zacks Equity Research

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Zacks Equity Research

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Zacks Equity Research

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

RGEN reports decent fourth-quarter results and issues guidance for 2025.

Zacks Equity Research

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

by Zacks Equity Research

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks Equity Research

BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View

by Zacks Equity Research

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

Zacks Equity Research

Novavax to Report Q4 Earnings: Here's What You Can Expect

by Zacks Equity Research

On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.